Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new intradermal immunotherapy for peanut allergy is showing promising results in kids. Aravax's PVX108 — which uses synthetic peptides instead of whole peanut proteins — increased maximum tolerated peanut doses by 2.4x compared to placebo, with no serious treatment-related adverse events reported in a phase 2 trial.
A novel peanut allergy treatment is turning heads at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Aravax's PVX108 takes a different approach from traditional immunotherapy — instead of using whole peanut proteins that can trigger dangerous reactions, it uses synthetic peptides that train the immune system to tolerate peanuts without setting off the alarm bells. The result? A simpler, safer monthly intradermal injection regimen.
In a phase 2 trial involving children aged 4 to 17, the 50 nmol dose of PVX108 increased maximum tolerated peanut doses by a factor of 2.4 at 12 months, compared to just 1.2x with placebo. Notably, 39.4% of the treatment group could tolerate a cumulative dose of 443 mg of peanut protein or more — roughly the equivalent of one to two peanuts — versus 16.7% of the placebo group. Emotional quality of life also improved significantly for treated children.
By the Numbers:
Why it matters: This is the first peanut-specific immunotherapy shown to be effective without containing actual peanut protein — a potential game-changer for the millions of children living with peanut allergy and the families navigating its daily emotional and safety burdens.
